Sundia MediTech (桑迪亚医药技术（上海）有限公司), a Shanghai-based CRO, and Xcovery of Florida reported that their two-year drug discovery collaboration has yielded four pre-clinical candidates, with two more that could be identified in the next three months. The results far surpassed the original timetable. Xcovery, a recent spin-off of The Scripps Research Institute, is focused on next-generation kinase therapeutics that will seek to treat inflammation and cancer. More details...